Surgery Versus Intra-lesional Sclerosis With Polidocanol (Aetoxisclerol) in Labial Venous Malformations in Children and Adults (SASOV)
Surgery Versus Intra-lesional Sclerosis With Polidocanol (Aetoxisclerol) in Labial Venous Malformations in Children and Adults: a Randomized Controlled Trial
The goal of this clinical trial is to learn if Surgery works better than Intra-lesional Sclerosis With Polidocanol to treat Labial Venous Malformations in Children and Adults. It will also learn about the safety of both approaches. The main questions it aims to answer are:
- Does Surgery has greater Global efficacy, including (including lesion volume reduction, scar quality, and lip symmetry) than Intra-lesional Sclerosis With Polidocanol?
- What complications do participants have when undergoing Surgery or Intra-lesional Sclerosis With Polidocanol? Researchers will compare surgery to Intra-lesional Sclerosis With Polidocanol.
Participants will be randomized to one of two treatment strategies:
- Experimental group: Surgical excision of the labial venous malformation (VM).
- Control group: Sclerotherapy strategy consisting of one or two sessions of intralesional polidocanol 3% injection.
Patients will be identified and recruited during multidisciplinary vascular anomalies clinics. The study protocol will be explained to eligible patients and their families. After obtaining written informed consent (or consent from both parents together with the child's assent, when applicable), participants will be enrolled in the study.
Following enrollment, participants will be randomly assigned to one of the two parallel treatment groups. A baseline assessment will be performed, and patients will receive a patient diary to record subjective outcomes, including pain, during the pre-intervention period until the date of the procedure.
Study follow-up visits will take place at 1 month (telemedicine visit), 3 months, and 12 months after treatment. Outcome assessments will be performed at each scheduled follow-up visit.
Visão geral do estudo
Status
Status
Condições
Condições
Intervenção / Tratamento
Intervenção / Tratamento
Tipo de estudo
Tipo de estudo
Inscrição (Estimado)
Inscrição
Estágio
Estágio
- Fase 3
Contactos e Locais
Contato de estudo
Contato de estudo
- Nome: Aline JOLY, MD
- Número de telefone: +332 47 47 38 21
- E-mail: a.joly@chu-tours.fr
Estude backup de contato
- Nome: Coralie TAILLEBUIS
- Número de telefone: +33247473909
- E-mail: c.taillebuis@chu-tours.fr
Locais de estudo
-
-
-
Paris, França
- Lariboisière
-
Contato:
- Annouk BISDORFF, MD
- Número de telefone: +331 49 95 84 50
- E-mail: annouk.bisdorff@aphp.fr
-
Contato:
- E-mail: a.joly@chu-tours.fr
-
Investigador principal:
- Annouk BISDORFF, MD
-
Paris, França
- Necker
-
Contato:
- Olivia BOCCARA, MD
- Número de telefone: +331 44 49 46 63
- E-mail: olivia.boccara@aphp.fr
-
Investigador principal:
- Olivia BOCCARA, MD
-
Tours, França
- CHRU de Tours
-
Contato:
- Aline JOLY, MD
- Número de telefone: +332 47 47 38 21
- E-mail: a.joly@chu-tours.fr
-
Contato:
- E-mail: a.joly@chu-tours.fr
-
Investigador principal:
- Aline JOLY, MD
-
-
Critérios de participação
Critérios de elegibilidade
Critérios de elegibilidade
Idades elegíveis para estudo
Aceita Voluntários Saudáveis
Gêneros Elegíveis para o Estudo
Descrição
Inclusion Criteria:
- Age ≥ 4 years
- Symptomatic venous malformation of the lower and/or upper lip
- Venous pocket with an area of between 10 and 50 mm²
- No history of surgery or interventional radiology in the area within the two years prior to inclusion
- Suitable for sclerotherapy and surgery
- Patient covered by the National Health Service
- Informed, written consent from the child's legal guardians or from the participant themselves if they are of legal age
Exclusion Criteria:
- Pregnant or breastfeeding women
- Women of childbearing age not using effective contraception throughout the study
- Patients under guardianship or curatorship, or subject to a court-ordered protective measure
- Other vascular abnormalities
- Contraindications to MRI
- Contraindications to Aetoxisclerol®
- Contraindications to general anaesthesia
- Contraindications to surgery
Plano de estudo
Como o estudo é projetado?
Detalhes do projeto
- Finalidade Principal: Tratamento
- Alocação: Randomizado
- Modelo Intervencional: Atribuição Paralela
- Mascaramento: Solteiro
Número de braços
Armas e Intervenções
Grupo de Participantes / BraçoGrupo de Participantes / Braço |
Intervenção / TratamentoIntervenção / Tratamento |
|---|---|
|
Experimental: Surgical strategy
Experimental group: Surgical strategy for the excision of the superficial venous malformation (SVM). The surgery involves either partial reconstructive excision or complete excision of the SVM, depending on its size. The aim is to restore symmetry to the affected side of the lip in order to correct functional impairments and aesthetic effects. |
The surgery is performed under local or general anaesthesia (depending on the size of the SVM and the patient's age). Various coagulation devices (monopolar forceps with a Colorado tip, bipolar scissors, etc.) are used to section and dissect the SVM and to control haemostasis. |
|
Comparador Ativo: Sclerotherapy strategy
Control group: Sclerotherapy strategy comprising one to two sessions of intra-lesional sclerotherapy with 3% polidocanol (Aetoxisclerol). |
The procedure may be carried out under local or general anaesthesia, depending on the patient's age, anticipated tolerance and in accordance with standard practice at the centre. The patient is positioned in the supine position. Following manual and visual localisation of the target lesion, one or more needles of 30/100th to 18G gauge are inserted, and their position within the lesion is confirmed by gentle aspiration, which should yield blood without resistance. The injection of an iodinated contrast medium suitable for intravenous use, to characterise the drainage and under fluoroscopic guidance in the angiography suite, is recommended but not mandatory. Once in place, ≤ 2 mg/kg of polidocanol is injected per session, i.e. ≤ 0.067 mL/kg of 3% solution distributed amongst the needles (1/2 to 2 ampoules), until thrombosis occurs, significant tension is felt in the lesion, or pain develops. Sclerotherapy may be repeated if necessary between 3 and 6 months after the first session. |
O que o estudo está medindo?
Medidas de resultados primários
Medidas de resultados primários
Medida de resultado |
Descrição da medida |
Prazo |
|---|---|---|
|
Global change
Prazo: From enrollment to Month 12 post intervention
|
Global change will be assessed 12 months after the intervention using a Likert scale ranging from -5 to +5 (0 = no improvement or worsening, higher scores mean better outcome), based on standardized pre- and post-intervention photographs. Assessments will be performed by an independent review panel comprising three physicians (one surgeon, one dermatologist, and one interventional radiologist) and one patient with a labial VM who did not participate in the study. The evaluation will be performed blinded to treatment allocation and will encompass changes in lesion volume, scar quality, and lip symmetry. A standardized photography protocol will be used. This primary endpoint (photograph-based assessment by an independent review panel) was selected to limit bias related to the open-label nature of the study, consistent with a PROBE design (Prospective Randomized Open, Blinded Endpoint). |
From enrollment to Month 12 post intervention
|
Medidas de resultados secundários
Medidas de resultados secundários
Medida de resultado |
Descrição da medida |
Prazo |
|---|---|---|
|
Aesthetic impact of the venous malformation
Prazo: Month 0 and Month 12
|
Assessment of aesthetic burden using a 0 to 10 visual analogue scale (VAS) with higher scores mean worse outcome, measured at baseline and 12 months after the intervention. |
Month 0 and Month 12
|
|
Functional impact: overall mouth function
Prazo: Month 0 and Month 12
|
Functional impact assessed using a 0 to 10 Visual Analogue Scale (VAS) for overall mouth function, with higher scores mean worse outcome |
Month 0 and Month 12
|
|
Functional impact: lip continence
Prazo: Month 0 and Month 12
|
Quantification of lip continence using a self-administered drooling questionnaire (Drooling Severity and Frequency Scale [DSFS]), score ranging from 2 to 9 with higher scores mean worse outcome |
Month 0 and Month 12
|
|
Functional impact: speech intelligibility
Prazo: Month 0 and Month 12
|
Speech intelligibility assessed using a self-administered questionnaire measuring speech-related intelligibility, the Intelligibility in Context Scale (ICS). Score ranging from 7 to 35, with higher scores mean better outcome |
Month 0 and Month 12
|
|
Overall patient satisfaction: Likert scale
Prazo: From enrollment to Month 12
|
Overall patient satisfaction assessed with a Likert scale ranging from -5 to +5 (0 = no improvement and no worsening), higher scores mean better outcome |
From enrollment to Month 12
|
|
Overall patient satisfaction: Goal Attainment Scale
Prazo: Month 12
|
Using achievement of personalized goals (maximum of three), predefined by the patient together with the investigator, assessed with the Goal Attainment Scale (GAS; scores ranging from -2 to +2, with higher scores mean better outcome). The Goal Attainment Scale (GAS) is a method for measuring treatment effectiveness by creating patient-specific outcome scales that are predefined before study participation. GAS aims to identify goals that are meaningful to the patient and related to their daily activities and individual priorities (Steinbook RM, 1977; DOI: 10.1001/archpsyc.1977.01770200061005). |
Month 12
|
|
Number of painful days: Total number of painful days
Prazo: The month (30 days) preceding the intervention, the month following the intervention, and the month preceding the 12-month post intervention visit (M12)
|
Total number of painful days assessed using either a patient diary or the online ePRO portal. |
The month (30 days) preceding the intervention, the month following the intervention, and the month preceding the 12-month post intervention visit (M12)
|
|
Number of painful days: Number of painful days with a VAS pain score > 3/10
Prazo: The month (30 days) preceding the intervention, the month following the intervention, and the month preceding the 12-month post-intervention visit (M12)
|
Number of painful days with a VAS pain score > 3/10 assessed using either a patient diary or the online ePRO portal. |
The month (30 days) preceding the intervention, the month following the intervention, and the month preceding the 12-month post-intervention visit (M12)
|
|
Venous Malformation volume on MRI
Prazo: Month 0 and Month 12
|
Venous malformation volume assessed before the intervention (within 6 months prior to treatment) and 12 months after the intervention (performed as part of routine care). Volumetric assessment will be conducted using a semi-automated thresholding method. Image analysis will be centralized and performed by an independent radiologist blinded to treatment allocation. |
Month 0 and Month 12
|
|
Coagulation: D-dimer
Prazo: Month 12
|
D-dimer |
Month 12
|
|
Coagulation: fibrinogen level
Prazo: Month 12
|
Fibrinogen level |
Month 12
|
|
Adverse events including complications
Prazo: From enrollment to Month 12
|
Safety including adverse events and complications, recorded using a patient diary or the online ePRO portal |
From enrollment to Month 12
|
|
Acceptability of the interventions
Prazo: Month 1, Month 3 , and Month 12
|
Acceptability of the interventions for the patient (or for parents in children aged < 6 years), assessed using a 0 to 10 Visual Analogue Scale (VAS), with higher scores mean worse outcome |
Month 1, Month 3 , and Month 12
|
|
Healthcare costs
Prazo: From enrollment to Month 12 following the intervention
|
In each arm, patients' healthcare utilization related to the procedure and outpatient care will be measured using hospital databases and a patient diary, then valued in euros from the perspective of the healthcare system. |
From enrollment to Month 12 following the intervention
|
Colaboradores e Investigadores
Patrocinador
Patrocinador
Datas de registro do estudo
Datas Principais do Estudo
Início do estudo (Estimado)
Início do estudo
Conclusão Primária (Estimado)
Conclusão Primária
Conclusão do estudo (Estimado)
Conclusão do estudo
Datas de inscrição no estudo
Enviado pela primeira vez
Enviado pela primeira vez
Enviado pela primeira vez que atendeu aos critérios de CQ
Enviado pela primeira vez que atendeu aos critérios de CQ
Primeira postagem (Real)
Primeira postagem
Atualizações de registro de estudo
Última Atualização Postada (Real)
Última Atualização Postada
Última atualização enviada que atendeu aos critérios de controle de qualidade
Última atualização enviada que atendeu aos critérios de controle de qualidade
Última verificação
Última verificação
Mais Informações
Termos relacionados a este estudo
Palavras-chave
Termos MeSH relevantes adicionais
Outros números de identificação do estudo
Outros números de identificação do estudo
- DR240317
- 2025 (Concessão/Contrato do NIH dos EUA)
- 2025-521374-34-00 (Ctis)
Plano para dados de participantes individuais (IPD)
Planeja compartilhar dados de participantes individuais (IPD)?
Informações sobre medicamentos e dispositivos, documentos de estudo
Estuda um medicamento regulamentado pela FDA dos EUA
Estuda um produto de dispositivo regulamentado pela FDA dos EUA
Essas informações foram obtidas diretamente do site clinicaltrials.gov sem nenhuma alteração. Se você tiver alguma solicitação para alterar, remover ou atualizar os detalhes do seu estudo, entre em contato com register@clinicaltrials.gov. Assim que uma alteração for implementada em clinicaltrials.gov, ela também será atualizada automaticamente em nosso site .